RSCM
ELVN icon

Rock Springs Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Rock Springs Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6M Sell
464,625
-361,875
-44% -$15.4M 1.15% 23
2026
Q1 		$32.4M Buy
826,500
+28,095
+4% +$778K 1.91% 15
2025
Q4 		$12.3M Buy
798,405
+112,298
+16% +$2.24M 0.63% 47
2025
Q3 		$14M Sell
686,107
-15,301
-2% -$308K 0.82% 45
2025
Q2 		$14.1M Buy
701,408
+235,537
+51% +$4.46M 0.88% 41
2025
Q1 		$9.17M Buy
465,871
+37,300
+9% +$803K 0.52% 54
2024
Q4 		$9.64M Hold
428,571
– – 0.37% 63
2024
Q3 		$10.9M Hold
428,571
– – 0.36% 63
2024
Q2 		$10M Hold
428,571
– – 0.3% 69
2024
Q1 		$7.54M Buy
+428,571
New +$6.58M 0.19% 83
2022
Q4 		– Sell
-210,601
Closed -$1.92M – 123
2022
Q3 		$1.92M Hold
210,601
– – 0.05% 113
2022
Q2 		$1.03M Hold
210,601
– – 0.03% 126
2022
Q1 		$1.58M Buy
210,601
+25
+0% +$165 0.04% 126
2021
Q4 		$1.9M Buy
210,576
+3,300
+2% +$43.3K 0.04% 129
2021
Q3 		$3.38M Buy
+207,276
New +$4.31M 0.07% 135
2021
Q1 		– Sell
-90,125
Closed -$7.95M – 158
2020
Q4 		$7.95M Buy
90,125
+389
+0.4% +$32.6K 0.17% 122
2020
Q3 		$7.3M Sell
89,736
-1,447
-2% -$131K 0.19% 115
2020
Q2 		$10.1M Sell
91,183
-20,301
-18% -$2.27M 0.28% 104
2020
Q1 		$7.15M Buy
+111,484
New +$7.1M 0.3% 88

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Rock Springs Capital Management's ELVN Position: Q2 2026 in Review

Rock Springs Capital Management reduced its Enliven Therapeutics (ELVN) stake by 44% in Q2 2026, selling an estimated $15.4M and leaving 464,625 shares worth $23.6M. The position accounts for 1.15% of the portfolio, ranked #23.

Rock Springs Capital Management first reported a position in ELVN in Q1 2020 and has held it in 19 quarters since. The position peaked at $32.4M in Q1 2026. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Rock Springs Capital Management held 464,625 shares of Enliven Therapeutics worth $23.6M as of Q2 2026.
  • Rock Springs Capital Management sold 361,875 Enliven Therapeutics shares in Q2 2026, an estimated $15.4M.
  • Enliven Therapeutics made up 1.15% of Rock Springs Capital Management's portfolio in Q2 2026, its #23 holding.
  • Rock Springs Capital Management first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 19 quarters since.
  • Rock Springs Capital Management's Enliven Therapeutics position peaked at $32.4M in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.